Organisation paid for research Program year 2023 Source: CMS Open Payments

Satish A Shah MD PC

Neither a doctor nor a teaching hospital

Research payments

$397,934

30 payments

Through program year 2023, Satish A Shah MD PC is reported as receiving $397,934 in research payments, across 30 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $27,220 8
2022 Research $47,126 15
2021 Research $54,089 3
2020 Research $209,645 2
2019 Research $59,853 2

Breakdown

Who paid Research payments · program years 2019–2023
  1. AstraZeneca AB $251,632 3 payments
  2. AstraZeneca Pharmaceuticals LP $75,111 2 payments
  3. EMD Serono, Inc. $23,795 13 payments
  4. Merck Healthcare KGaA $21,680 5 payments
  5. Janssen Research & Development, LLC $15,715 5 payments
  6. Regeneron Pharmaceuticals, Inc. $9,000 1 payment
  7. Sobi, Inc $1,000 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Advanced Prostate Cancer $251,632 3 payments
  2. A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST) $75,111 2 payments
  3. A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) $21,680 5 payments
  4. Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer $15,715 5 payments
  5. A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy Definitive Chemoradiotherapy (TrilynX) $14,440 7 payments
  6. A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy & Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of Head & Neck $9,355 6 payments
  7. A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 Cemiplimab Anti-PD-1 Antibody and Ipilimumab Anti-CTLA-4 Antibody in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer $9,000 1 payment
  8. Ava-Cit-330 $1,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record